HaystackAnalytics unveils ‘TB One’ solution to strengthen India's TB control efforts

A next-generation solution (NGS) empowering labs and hospitals with genomic sequencing capabilities

In a move to bolster India's fight against tuberculosis (TB), Mumbai-based startup HaystackAnalytics has introduced ‘TB One,’ a Make-in-India solution designed to enhance TB diagnosis by enabling Next-Generation Sequencing (NGS) at any diagnostic lab or hospital.

This all-in-one offering includes a pre-sequencing kit for Whole Genome Sequencing (WGS), access to ‘Omega TB’—HaystackAnalytics’ patented clinical reporting software—and on-demand access to 2GB of sequencing data.

The Omega TB software delivers a comprehensive clinical report covering resistance to 18 anti-TB drugs, along with mixed infections, non-tuberculous mycobacteria (NTM), and heteroresistance—all within a single, standardized report. By equipping healthcare providers with precise, data-driven insights, ‘TB One’ aims to improve TB management and strengthen India’s fight against the disease.

The Solution has been unveiled by Dr Anirvan Chatterjee, Co-founder & CEO, HaystackAnalytics & Dr Rajendra Prasad at Indian Council of Medical Research's (ICMR) India Innovation Summit: Pioneering Solutions to End TB on March 19, 2025.

With this solution genomics-based TB testing would become more accessible and scalable by enabling existing laboratories to upgrade to NGS testing for TB without significant infrastructure changes. This solution aligns seamlessly with HaystackAnalytics' mission to make genomics accessible, applicable, and affordable, addressing a critical need to transform molecular diagnostic laboratories into advanced genomic facilities.

‘TB One’ Solution is a pre-sequencing kit that enables the preparation of a ready-to-sequence library from TB DNA. It simplifies the complex process of genomic testing, allowing laboratories and hospitals to integrate groundbreaking technology into their existing workflows. This advancement enables laboratories to conduct comprehensive drug resistance profiling with unprecedented precision and efficiency.  

Published on : 20th March, 2025